RxDoctor Payments Data

Francis Ashie, MD

Family Medicine · Rockledge, FLNPI 1487602082

Payments from drug & device makers

$778in general payments, 2019–2025

Across 15 payments — averaging $51.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$155
  • Genentech USA, Inc.$146
  • Takeda Pharmaceuticals U.S.A., Inc.$109
  • Seagen Inc.$101
  • AstraZeneca$100
  • Novo Nordisk$96
  • plus $71 from 3 others

What the payments were for

  • Food & beverage$74796%
  • Education$324%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$778 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$199,858
Medicare patients
123
Services billed
2,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide107$124,522
OzempicSemaglutide31$37,604
EliquisApixaban27$35,174
LinzessLinaclotide17$22,021
FarxigaDapagliflozin Propanediol13$15,839
JardianceEmpagliflozin12$14,396
JanuviaSitagliptin Phosphate17$14,105
XareltoRivaroxaban14$10,623
Lurasidone Hcl13$10,537
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen205$9,021
Oxycodone Hcl157$3,540
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl12$3,365
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen108$3,298
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide114$1,772
Pantoprazole Sodium96$1,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$16$124,522107 claims
Novo NordiskOzempic$96$37,60431 claims
PfizerEliquis$28$35,17427 claims
AbbVieLinzess$155$22,02117 claims
AstraZenecaFarxiga$100$15,83913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Rockledge

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →